
Bristol Myers bets $475M cash on a blockbuster shot at breaking the mold in immuno-oncology — with a potential IL-12 game-changer
In the oncology R&D world, IL-12 has a rep something akin to nitroglycerine in old Hollywood movies. It’s incredibly powerful, but any false move and … kaboom.
You’re dead.
That makes it the perfect kind of target for drug hunters who like a big challenge, particularly when you’re using it to orchestrate an immune response in a tumor — the classic Holy Grail in these post-PD-(L)1 approval days as investigators try to stack immuno-oncology strategies. And nobody knows that better than Bristol Myers Squibb, which has two of the original checkpoint stars in the portfolio.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.